FULC vs OVID Comparison

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.